Notice of Intent to Sole Source
The Centers for Disease Control and prevention intends to award a sole source firm fixed price purchase order to Illumina, Inc. for procurement of yearly service agreement from Illumina for MiSeq Equipment currently used in the laboratory supporting molecular genetic studies of hemophilia, hemoglobinopathies, and other bleeding disorders. No other service exists for the Illumina genotypin platform in the laboratory. Illumina, Inc. genotyping system is proprietary. The continued functionality and timely repair of this equipment is necessary to support molecular genetic studies of hemophilia, hemoglobinopathies, and other bleeding and clotting disorders. This contract action is for supplies or services for which the Government intends to solicit and negotiate with only one source under the authority of FAR 13.106-1(b) and 10 U.S.C. 2304(c)(1). Interested persons may identify their interest and capability to respond to the requirement or submit proposals.
This notice of intent is not a request for competitive quotations; however, all quotations/responses received within ten (10) days of the issuance of this notice will be considered by the government. A determination by the government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement. Any quotation/response should be emailed to contract specialist at [email protected] by 5:00 P.M EST., May 30th, 2014.
FAR REFERENCE: FAR 5.207- Preparation and transmittal of synopses under (c)(15), (c)(16) (i), and (c)(16)(ii).
William T. Brannen, Phone 7704882084, Email [email protected] - Lawrence R. McCoy, Contracting Officer, Phone 770-488-2087, Fax 770-488-2670, Email [email protected]
